Best of ASCO - 2014 Annual Meeting

 

Welcome

Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Frequency of NOTCH pathway mutation in primary tumor of SCLC compared to metastatic biopsies and association with better survival.

Fatemeh Ardeshir-Larijani

e20574

FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer.

Jiuwei Cui

e20573

A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.

YuJung Kim

8575

A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer.

Martin J. Edelman

TPS8588

ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.

Anna F. Farago

TPS8587

Clinical implications of cell free DNA concentration in patients with small cell lung cancer.

Wade Thomas Iams

e20563

Differences in small cell lung cancer genetic profile between disease progression (PD) and partial remission (PR) patients after the standard first-line chemotherapy.

Yalei Zhang

e20565

Early assessment of therapy response in small cell lung cancer via longitudinal ctDNA analysis.

John F. Palma

8577

Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.

Jose Manuel Trigo Perez

8570

Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.

David Paul Carbone

8507

Genomic evolutions in the progression from lung preneoplasia to adenocarcinoma.

Xin Hu

8576

Identifying treatment options for SCLC patients with multiplexed clinical proteomic testing.

Eunkyung An

8574

Improved survival of small cell lung cancer in the veterans health administration from 2000-2010: Association with increasing utilization of PET staging.

Julian C. Hong

e20571

Incidence of pre-treatment and off-treatment pericardial and pleural effusions by line of therapy in patients with small cell lung cancer: An analysis of electronic health records data.

Rui Jiang

e20569

Large-scale nationwide genomic screening system for small cell lung cancer in Japan (LC-SCRUM-Japan).

Yukari Ogawa

8572

Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden.

Joshua K. Sabari

e20568

Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).

Nicolas Marcoux

8573

PARP1 expression in high-grade neuroendocrine carcinoma of the lung.

Hye Sook Kim

e20562

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Hyun Cheol Chung

8506

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for patients with extensive-stage small cell lung cancer.

Chul Kim

TPS8589

QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.

Sukhmani Kaur Padda

e20575

Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).

Jonathan Wade Goldman

8518

Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).

Daniel C. Cho

8517

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

Anna F. Farago

8571

Safety of use of granulocyte colony stimulating factor during concurrent chemotherapy and thoracic radiotherapy in limited-stage small-cell lung cancer.

Roma Srivastava

e20570

Survival outcomes among young small cell lung cancer (SCLC) patients and insurance status: A SEER analysis 2007-2014.

Qian Wang

e20566

The role of surgery for stage I small cell lung cancer in recent years: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Dipesh Uprety

e20576

Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017.

Mickaël Lattuca-Truc

e20572

What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.

Donald A. Richards

e20567